Compare First Solar, Inc. (FSLR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? First Solar, Inc. trades at $178.12 (market cap $19.22B), while Recursion Pharmaceuticals Inc trades at $4.33 (market cap $2.14B). The key difference: First Solar, Inc. is far larger — about 9× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, First Solar, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Solar, Inc. for 76 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| FSLR | RXRX | |
|---|---|---|
Market Cap | $19.22B | $2.14B |
Volume | 2,067,793 | 30,789,535 |
Sector | Energy | Health |
52-Week High | $318.30 | $6.79 |
52-Week Low | $172.11 | $2.84 |
Typical Hold Time | 76 Days | 23 Days |
Enterprise Value | $17.69B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $178.36, down 0.98% with bearish technical signals despite strong fundamentals. The stock shows robust revenue growth from $2.6B in 2022 to $5.2B in 2025, with net income margins expanding to 32.47%. Recent patent litigation against JA Solar and increased put option activity reflect mixed sentiment. Technical indicators show resistance at $182 and support at $175, with moving averages signaling bearish momentum.
FSLR presents a value opportunity with attractive valuation ratios (P/E 11.03, P/S 3.58) and analyst consensus price target of $267.59 (50% upside). Risks include sector-wide pressure from high borrowing costs and political uncertainty. Strong cash flow generation ($2.06B operating cash flow) and consistent earnings beats support long-term growth prospects despite near-term technical weakness.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
